Kinesiotaping Effect Glenohumeral Shoulder Subluxation

The Effect of Kinesiotaping on Glenohumeral Shoulder Subluxation in Post-stroke Patients

To evaluate the effectiveness of the kinesiotaping on pain, recovery of movement and daily life activities in Turkish hemiplegic patients.

Study Overview

• Status: Completed
• Conditions: Stroke; Subluxation, Glenohumeral
• Intervention / Treatment: Device: kinesiotape

• Study Type: Interventional
• Enrollment (Actual): 14
• Phase: Not Applicable

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 90 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• (1) 18 to 90 years of age, (2) stroke onset within one year, (3) shoulder subluxation in the involved upper extremity and (4) being oriented and cooperative.

Exclusion Criteria:

• (1) global aphasia, (2) malignancy, (3) previous shoulder pain or surgery, (4) other neuromuscular disorders and (5) severe cardiopulmonary disease that affects daily life activities.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Kinesiotape; Kinesiotape (Nasara, Korea) was applied for three times a week (Monday, Wednesday, and Friday) for three weeks.	Device: kinesiotape; During the rehabilitation program, all patients with GHS had kinesiotaping three times a week.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Subluxation degree by physical examination	A clinician measured the gap between the acromion and the humeral head with the fingerbreadth at the distal interphalangeal joint of the right index and middle fingers	0-3weeks
Subluxation degree by radiograph	The anterio-posterior shoulder X-ray was taken in an erect position, and subluxation was evaluated by Van Langenberghe's five point classification.	0-3weeks
physical examination	Passive range of motion (Flexion and Abduction)	0-3weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluation of the pain of the shoulder	Pain with motion was measured by a verbal descriptive pain scale. The VDPS was developed by Melzack and Katz and is composed of words such as "mild" (level 1) to "very severe pain" (level 5)	0-3weeks
Evaluation of Daily life activities	Daily life activities were evaluated using the Katz index of independence in activities of daily living, which evaluates the patients in bathing, dressing, toileting, transferring, continence, and eating. Activities were scored as zero or one with the total score ranging from zero to six. Higher scores are related with higher independency.	0-3weeks

Collaborators and Investigators

• Sponsor: Ankara Physical Medicine and Rehabilitation Education and Research Hospital
• Collaborators: Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
• Investigators: Study Director: Halil Ucan, MD, Ankara Physical Medicine and Rehabilitation Education and Research Hospital

Study record dates

Study Major Dates

• Study Start (Actual): November 13, 2013
• Primary Completion (Actual): July 15, 2015
• Study Completion (Actual): June 6, 2018

Study Registration Dates

• First Submitted: July 9, 2020
• First Submitted That Met QC Criteria: July 9, 2020
• First Posted (Actual): July 13, 2020

Study Record Updates

• Last Update Posted (Actual): July 14, 2020
• Last Update Submitted That Met QC Criteria: July 11, 2020
• Last Verified: July 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Wounds and Injuries; Joint Diseases; Musculoskeletal Diseases; Shoulder Injuries; Joint Dislocations; Shoulder Dislocation
• Other Study ID Numbers: 5416

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No